Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata, 700032, WB, India.
Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata, 700032, WB, India; Academy of Scientific and Innovative Research, Ghaziabad, 201002, India.
Eur J Med Chem. 2020 Sep 15;202:112551. doi: 10.1016/j.ejmech.2020.112551. Epub 2020 Jul 2.
We have recently reported a new chemotype of a potent topoisomerase I poison with compound 1 as a potential anticancer chemotherapeutic agent. During further optimization, it has been observed that compound 1 suffers from high intrinsic clearance in human liver microsomes. To overcome the metabolic instability of compound 1, we report design and synthesis of metabolically stable Top1 poison 3. Newly identified Top1 poison 3 exhibits t of 69.1 min in human liver microsomes in comparison to compound 1 with t of 9.9 min. Molecular dynamic study of the newly optimized Top1 poison 3 was performed to get the insight into the stability of the binding pose in the active site. Compound 3 was able to trap DNA-Top1 cleavage complex and found to be less cytotoxic in non-cancerous cell line as compared to compound 1.
我们最近报道了一种新型拓扑异构酶 I 强效抑制剂化合物 1,它可能成为一种有潜力的抗癌化疗药物。在进一步优化过程中,我们观察到化合物 1 在人肝微粒体中具有较高的内在清除率。为了克服化合物 1 的代谢不稳定性,我们设计并合成了代谢稳定的拓扑异构酶 I 抑制剂 3。与化合物 1 的 t1/2 为 9.9 分钟相比,新鉴定的拓扑异构酶 I 抑制剂 3 在人肝微粒体中的 t1/2 为 69.1 分钟。对新优化的拓扑异构酶 I 抑制剂 3 进行了分子动力学研究,以深入了解其在活性部位的结合构象的稳定性。化合物 3 能够捕获 DNA-拓扑异构酶 I 断裂复合物,并且与化合物 1 相比,在非癌细胞系中细胞毒性较小。